# Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Study · id `cardio:ct-nct02970669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02970669](<https://clinicaltrials.gov/study/NCT02970669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02970669

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT02970669. Randomized; double masking; primary purpose other. Start 2016-12-16 (actual); primary completion 2018-03-19 (actual). Results posted on 2019-04-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose other
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Started: 2016-12-16 (actual) (ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Primary completion: 2018-03-19 (actual) (ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Completion: 2018-03-19 (actual) (ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Results first posted: 2019-04-08 (ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02970669, source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02970669-2021-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
- Acronym: AWAKE-HF
- Condition: Heart Failure, Reduced Ejection Fraction
- Intervention (Drug): sacubitril/valsartan (LCZ696)
- Intervention (Drug): enalapril
- Intervention (Drug): matching placebo sacubitril/valsartan (LCZ696)
- Intervention (Drug): matching placebo enalapril
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure (`cardio:pubmed-32978755`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2b71eba5f84fcb4ab2afc85def1541b2f0294eb6f9533f63f2fd1760141500e3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
